Literature DB >> 12852429

Achieving low target pressures with today's glaucoma medications.

Louis Cantor1.   

Abstract

In the 21st century there are more highly effective medical management options for glaucoma than there were in the 1980s and 1990s. In deciding among them, the clinician's challenge is to select what is clinically relevant from the large amounts of available data. In evaluating different drugs the clinician must consider not only the mean intraocular pressure (IOP) of a trial population, but also the percentage of patients achieving clinically relevant low IOPs. The consistency of IOP control throughout the day and night is also critical. Other factors such as safety, tolerability, and cost-effectiveness must also be kept in mind, with an awareness (both in human and monetary terms) of the cost of treatment failure. This overview concludes that newer medical regimens for IOP lowering address efficacy and safety issues more successfully than older ones.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12852429     DOI: 10.1016/s0039-6257(03)00009-2

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  6 in total

1.  A Self-Assembling Injectable Biomimetic Microenvironment Encourages Retinal Ganglion Cell Axon Extension in Vitro.

Authors:  Melissa R Laughter; David A Ammar; James R Bardill; Brisa Pena; Malik Y Kahook; David J Lee; Daewon Park
Journal:  ACS Appl Mater Interfaces       Date:  2016-08-02       Impact factor: 9.229

Review 2.  Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis.

Authors:  Jin-Wei Cheng; Gui-Lin Xi; Rui-Li Wei; Ji-Ping Cai; You Li
Journal:  Curr Ther Res Clin Exp       Date:  2009-08

3.  Initial central scotomas vs peripheral scotomas in normal-tension glaucoma: clinical characteristics and progression rates.

Authors:  H-K Cho; J Lee; M Lee; C Kee
Journal:  Eye (Lond)       Date:  2013-12-20       Impact factor: 3.775

4.  Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis.

Authors:  John G Walt; Jacob T Wilensky; Richard Fiscella; Tina H Chiang; Angela Guckian
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

5.  Comparing the efficacy of the monocular trial treatment paradigm with multiple measurements of intraocular pressure before and after treatment initiation in primary open-angle glaucoma.

Authors:  Rohit Krishna; Peter W Debry; Corey W Waldman; Peter Koulen
Journal:  Clin Ophthalmol       Date:  2012-03-28

6.  Progression rate of total, and upper and lower visual field defects in open-angle glaucoma patients.

Authors:  Takeo Fukuchi; Takaiko Yoshino; Hideko Sawada; Masaaki Seki; Tetsuya Togano; Takayuki Tanaka; Jun Ueda; Haruki Abe
Journal:  Clin Ophthalmol       Date:  2010-11-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.